<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2010-09-14" updated="2020-01-02">
  <drugbank-id primary="true">DB06811</drugbank-id>
  <name>Polidocanol</name>
  <description>Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins â‰¤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena. The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.</description>
  <cas-number>9002-92-0</cas-number>
  <unii>0AWH8BFG9A</unii>
  <average-mass>582.8073</average-mass>
  <monoisotopic-mass>582.434298204</monoisotopic-mass>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7122</ref-id>
        <pubmed-id>22620717</pubmed-id>
        <citation>Peterson JD, Goldman MP, Weiss RA, Duffy DM, Fabi SG, Weiss MA, Guiha I: Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatol Surg. 2012 Aug;38(8):1322-30. doi: 10.1111/j.1524-4725.2012.02422.x. Epub 2012 May 23.</citation>
      </article>
      <article>
        <ref-id>A7123</ref-id>
        <pubmed-id>21605244</pubmed-id>
        <citation>Weiss RA, Voigts R, Howell DJ: Absence of concentration congruity in six compounded polidocanol samples obtained for leg sclerotherapy. Dermatol Surg. 2011 Jun;37(6):812-5. doi: 10.1111/j.1524-4725.2011.01906..x.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L144</ref-id>
        <title>Link</title>
        <url>http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_113.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity. </indication>
  <pharmacodynamics>Polidocanol has a concentration and volume dependent damaging effect on the blood vessel endothelium. </pharmacodynamics>
  <mechanism-of-action>When administered, polidocanol locally damages blood vessel endothelium. Following the endothelial damage, platelets aggregate at the site and attach to the venous wall eventually resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Eventually the vessel is replaced by connective fibrous tissue.</mechanism-of-action>
  <toxicity>Most adverse reactions are related to the intravenous administration such as local irritation, pain, and hematoma. Extravasation can also be an issue.</toxicity>
  <metabolism>Metabolism was not measured.</metabolism>
  <absorption>When given intravenously, the maximum blood concentrations were reached in 15 mins.</absorption>
  <half-life>The half-life is approximately 1.5 h. </half-life>
  <protein-binding>Plasma protein binding was not measured.</protein-binding>
  <route-of-elimination>Route of elimination was not indicated.</route-of-elimination>
  <volume-of-distribution>When given intravenously, the volume of distribution was 35-82L.</volume-of-distribution>
  <clearance>Sytemic clearance was 0.2-0.4 L/min.</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as polyethylene glycols. These are oligomers or polymers of ethylene oxide, with the general formula (C2H4O)n (with n&gt;=3).</description>
    <direct-parent>Polyethylene glycols</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic oxygen compounds</superclass>
    <class>Organooxygen compounds</class>
    <subclass>Ethers</subclass>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Polyethylene glycol</substituent>
    <substituent>Primary alcohol</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Aethoxy-sklerol</synonym>
    <synonym language="english" coder="">Laureth 9</synonym>
    <synonym language="english" coder="">Laureth-9</synonym>
    <synonym language="english" coder="">Macrogol 9 lauryl ether</synonym>
    <synonym language="english" coder="">Nonaethylene glycol monododecyl ether</synonym>
    <synonym language="english" coder="">Nonaethylene glycol monolauryl ether</synonym>
    <synonym language="english" coder="">PEG-9 lauryl ether</synonym>
    <synonym language="english" coder="">Polydocanol</synonym>
    <synonym language="english" coder="">Polyethylene glycol 450 lauryl ether</synonym>
    <synonym language="english" coder="">Polyoxyl 9 lauryl ether</synonym>
  </synonyms>
  <products>
    <product>
      <name>Asclera</name>
      <labeller>Merz North America, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>46783-221</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.01000 g/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021201</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Asclera</name>
      <labeller>Merz North America, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>46783-121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>0.00500 g/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021201</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Varithena</name>
      <labeller>Biocompatibles, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60635-118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>180 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA205098</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Varithena</name>
      <labeller>Biocompatibles, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60635-133</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>180 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA205098</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Varithena</name>
      <labeller>Provensis Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02444267</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>1.3 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Varithena TM</name>
      <labeller>Biocompatibles, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60635-123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>180 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA205098</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Aethoxysklerol</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Varithena</name>
      <ingredients>Polidocanol</ingredients>
    </mixture>
    <mixture>
      <name>Varithena</name>
      <ingredients>Polidocanol</ingredients>
    </mixture>
    <mixture>
      <name>Varithena TM</name>
      <ingredients>Polidocanol</ingredients>
    </mixture>
    <mixture>
      <name>Asclera</name>
      <ingredients>Polidocanol</ingredients>
    </mixture>
    <mixture>
      <name>Asclera</name>
      <ingredients>Polidocanol</ingredients>
    </mixture>
    <mixture>
      <name>Varithena</name>
      <ingredients>Polidocanol</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Antivaricose Therapy</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Detergents</category>
      <mesh-id>D003902</mesh-id>
    </category>
    <category>
      <category>Ethylene Glycols</category>
      <mesh-id>D005026</mesh-id>
    </category>
    <category>
      <category>Glycols</category>
      <mesh-id>D006018</mesh-id>
    </category>
    <category>
      <category>Household Products</category>
      <mesh-id>D006795</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Pegylated agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pharmaceutical Preparations</category>
      <mesh-id>D004364</mesh-id>
    </category>
    <category>
      <category>Pharmaceutical Solutions</category>
      <mesh-id>D019999</mesh-id>
    </category>
    <category>
      <category>Polyethylene Glycols</category>
      <mesh-id>D011092</mesh-id>
    </category>
    <category>
      <category>Polymers</category>
      <mesh-id>D011108</mesh-id>
    </category>
    <category>
      <category>Sclerosing Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sclerosing Agents for Local Injection</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sclerosing Solutions</category>
      <mesh-id>D012597</mesh-id>
    </category>
    <category>
      <category>Solutions</category>
      <mesh-id>D012996</mesh-id>
    </category>
    <category>
      <category>Surface-Active Agents</category>
      <mesh-id>D013501</mesh-id>
    </category>
    <category>
      <category>Vascular Sclerosing Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Vasoprotectives</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>0.00500 g/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>0.01000 g/1mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>1.3 mg</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>180 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="C05BB02">
      <level code="C05BB">Sclerosing agents for local injection</level>
      <level code="C05B">ANTIVARICOSE THERAPY</level>
      <level code="C05">VASOPROTECTIVES</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>24:16.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>3dm8</pdb-entry>
    <pdb-entry>5k9d</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB06811.pdf?1367014074</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB06811.pdf?1367014074</msds>
  <patents>
    <patent>
      <number>7814943</number>
      <country>United States</country>
      <approved>2010-10-19</approved>
      <expires>2027-11-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7842282</number>
      <country>United States</country>
      <approved>2010-11-30</approved>
      <expires>2020-05-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7604185</number>
      <country>United States</country>
      <approved>2009-10-20</approved>
      <expires>2020-05-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7357336</number>
      <country>United States</country>
      <approved>2008-04-15</approved>
      <expires>2020-05-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7025290</number>
      <country>United States</country>
      <approved>2006-04-11</approved>
      <expires>2020-05-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6572873</number>
      <country>United States</country>
      <approved>2003-06-03</approved>
      <expires>2020-05-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7731986</number>
      <country>United States</country>
      <approved>2010-06-08</approved>
      <expires>2024-11-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>RE40640</number>
      <country>United States</country>
      <approved>2009-02-17</approved>
      <expires>2016-10-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8734833</number>
      <country>United States</country>
      <approved>2014-05-27</approved>
      <expires>2020-05-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8122917</number>
      <country>United States</country>
      <approved>2012-02-28</approved>
      <expires>2024-09-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6942165</number>
      <country>United States</country>
      <approved>2005-09-13</approved>
      <expires>2020-05-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8323677</number>
      <country>United States</country>
      <approved>2012-12-04</approved>
      <expires>2020-05-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6846412</number>
      <country>United States</country>
      <approved>2005-01-25</approved>
      <expires>2022-07-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7842283</number>
      <country>United States</country>
      <approved>2010-11-30</approved>
      <expires>2020-05-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9480652</number>
      <country>United States</country>
      <approved>2016-11-01</approved>
      <expires>2032-05-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00019</drugbank-id>
      <name>Pegfilgrastim</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegfilgrastim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegaspargase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00061</drugbank-id>
      <name>Pegademase</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegademase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegvisomant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01839</drugbank-id>
      <name>Propylene glycol</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Propylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03394</drugbank-id>
      <name>Heptaethylene glycol</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegaptanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05202</drugbank-id>
      <name>Egaptivon pegol</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Egaptivon pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05321</drugbank-id>
      <name>PEG-uricase</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05860</drugbank-id>
      <name>Peginterferon alfacon-1</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Peginterferon alfacon-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06022</drugbank-id>
      <name>GlycoPEG-GCSF</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with GlycoPEG-GCSF.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06293</drugbank-id>
      <name>Pegnivacogin</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegnivacogin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06325</drugbank-id>
      <name>Pegpleranib</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegpleranib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06611</drugbank-id>
      <name>Pegsunercept</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegsunercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The therapeutic efficacy of Peginesatide can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09208</drugbank-id>
      <name>Pegloticase</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11661</drugbank-id>
      <name>Eptacog alfa pegol (activated)</name>
      <description>The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11707</drugbank-id>
      <name>Olaptesed Pegol</name>
      <description>The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12258</drugbank-id>
      <name>Abicipar Pegol</name>
      <description>The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12578</drugbank-id>
      <name>Lexaptepid Pegol</name>
      <description>The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12839</drugbank-id>
      <name>Pegvaliase</name>
      <description>The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12842</drugbank-id>
      <name>Pegamotecan</name>
      <description>The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13200</drugbank-id>
      <name>Lipegfilgrastim</name>
      <description>The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13933</drugbank-id>
      <name>Nonacog beta pegol</name>
      <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14700</drugbank-id>
      <name>Damoctocog alfa pegol</name>
      <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14712</drugbank-id>
      <name>Elapegademase</name>
      <description>The therapeutic efficacy of Elapegademase can be decreased when used in combination with Polidocanol.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.15</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-6.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.03e-04 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.94</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>3,6,9,12,15,18,21,24,27-nonaoxanonatriacontan-1-ol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>polidocanol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>582.8073</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>582.434298204</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C30H62O10</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C30H62O10/c1-2-3-4-5-6-7-8-9-10-11-13-32-15-17-34-19-21-36-23-25-38-27-29-40-30-28-39-26-24-37-22-20-35-18-16-33-14-12-31/h31H,2-30H2,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>ONJQDTZCDSESIW-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>103.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>158.33</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>74.49</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>37</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>10</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>15.12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-2.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>miscible </value>
      <source>http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_113.pdf</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>33-36 Â°C</value>
      <source/>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>615.857 Â°C at 760 mmHg</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.94</value>
      <source># http://www.chemicalize.org/structure/#!mol=polidocanol</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12518</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>46859</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>656641</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>175427093</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C13493</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01993</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>570993</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>CE9</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Polidocanol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1231723</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/asclera-drug.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/info/v1us/asclera</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/international/asclera.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>